Home Featured Page 4

Featured

Latest

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD Microdosing No Better than Placebo in ADHD

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta Sophia Becomes USPTO Information Source

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant...

2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

The Psychedelic News Feed: September 2, 2024 – December 29, 2024

Psychedelic Drug Development Pipeline Updates (Q1’25)

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart

How Do You Find the Right Facilitator? The Art of Matchmaking...

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics...

Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes...

Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule...

Psychedelics in 2024: From Hype to Hard Realities

1...345...283 Page 4 of 283

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Fayzan Rab – Emory University

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD Microdosing No Better than Placebo in ADHD

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta Sophia Becomes USPTO Information Source

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant...

2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

The Psychedelic News Feed: September 2, 2024 – December 29, 2024

Psychedelic Drug Development Pipeline Updates (Q1’25)

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart

How Do You Find the Right Facilitator? The Art of Matchmaking...

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics...

Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes...

Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule...

Psychedelics in 2024: From Hype to Hard Realities

EDITOR PICKS

Fayzan Rab – Emory University

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY